Immuneering Corporation (IMRX) Misses Q4 EPS by 13c

Immuneering Corporation (NASDAQ: IMRX) reported Q4 EPS of ($0.58), $0.13 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Immuneering Corporation (IMRX) click here.

You May Also Be Interested In

• Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
• Citi raises Broadcom price target to $515 amid AI outlook
• Brady Corp. (BRC) Tops Q4 EPS by 1c ; Offers Guidance